Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
ADC Therapeutics SA
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
Prev close 1.08 · gapped below the open, then crossed back over prior close. High/low 1.08 at 4:00 pm ET, 1.03 at 12:45 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“AmerisourceBergen Corporation (1) 39 % 35 %”
$28M relationship
basisADCT fy2024 · closed 2024-12 $71M
FILING10-K0001628280-26-016491cik 0001771910
“McKesson 39 % 41 %”
$28M relationship
basisADCT fy2024 · closed 2024-12 $71M
FILING10-K0001628280-26-016491cik 0001771910
“Cardinal Health 22 % 24 %”
$16M relationship
basisADCT fy2024 · closed 2024-12 $71M
FILING10-K0001628280-26-016491cik 0001771910
“Our current ZYNLONTA pipeline utilizes our highly potent pyrrolobenzodiazepine ("PBD") dimer technology (under license from AstraZeneca).”
FILING10-K0001628280-26-016491cik 0001771910
“On August 25, 2021, we entered into a royalty purchase agreement with certain entities managed by Healthcare Royalty Partners ("HCR").”
FILING10-K0001628280-26-016491cik 0001771910
“Under the terms of the agreement, MedImmune has granted us an exclusive, worldwide license under certain patent rights and related know-how to make, have made, use, sell, offer for sale and import product candidates in the field of human therapeutics and diagnostics that consist of (i) PBD-based molecules directly conjugated to an antibody (i.e., ADCs with a PBD-based warhead) that specifically bind to up to 11 approved targets ("ADC Targets"), and (ii) PBD-based molecules conjugated to a non-antibody (i.e., targeting-moiety conjugates with a PBD-based warhead) that specifically bind to up to ten approved targets ("XDC Targets").”
FILING10-K0001628280-26-016491cik 0001771910
“In 2011, we (then operating under the name ADCT Sàrl) entered into a license and collaboration agreement with Spirogen (since renamed ADC Products UK Ltd.), pursuant to which Spirogen granted us access to its next-generation PBD-based warhead and linker technology.”
FILING10-K0001628280-26-016491cik 0001771910
“We are required to use diligent efforts to manufacture and supply to Overland ADCT BioPharma (at our manufacturing cost), and Overland ADCT BioPharma must purchase from us, all of Overland ADCT BioPharma's requirements of the Licensed Products for its development and commercialization activities.”
FILING10-K0001628280-26-016491cik 0001771910
“In March 2025, the Company recognized $5.0 million in license revenue in connection with a milestone due upon ZYNLONTA's conditional approval by Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy, which was paid to us by Sobi in the second quarter of 2025.”
FILING10-K0001628280-26-016491cik 0001771910
“In January 2022, we entered into a license agreement with TPC, to develop and commercialize ZYNLONTA in Japan, pursuant to which we granted TPC an exclusive license under all applicable patents and know-how relating to ZYNLONTA in order to use, sell, offer for sale, import and commercialize ZYNLONTA for all cancer indications in Japan.”
FILING10-K0001628280-26-016491cik 0001771910
“The Company determined that the ADC Therapeutics (ADCT) agreement falls within the scope of ASC 606.”
FILING10-K0001193125-26-092614cik 0001799448disclosed by ALGS
“The Company agreed to supply product to Overland ADCT BioPharma for its drug development and commercialization under a supply agreement entered into between the parties.”
FILING10-K0001628280-26-016491cik 0001771910
Watchlist prices, news filtered to it, and its next report on your desk.
ADC Therapeutics SA has 5 disclosed suppliers and 7 disclosed customers. Each one is named in an SEC filing, either ADC Therapeutics SA’s own annual report or the counterparty’s, and carries the sentence that discloses it.
ADCT (ADC Therapeutics SA) has 5 disclosed suppliers and 7 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ALGS −1.39%, in healthcare.